Title : Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.

Pub. Date : 2017 Jul 15

PMID : 28506030






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. Ribavirin interferon alpha 1 Homo sapiens